Slide 1: Corporate Presentation March 2026
Corporate Presentation March 2026
Slide 2: Safe Harbor
Safe Harbor This presentation contains “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptio
Slide 3: Diversified Provider of Ophthalmic Disease Management Solutions in North America
Diversified Provider of Ophthalmic Disease Management Solutions in North America Key revenue drivers are best- Scalable commercial platform Largest U.S. portfolio of prescription ophthalmic in-class products with large with an innovative market products broadly covering the ophthalmic anatomy access
Slide 4: Investment Highlights
Investment Highlights Durable Revenue Drivers and a 2026–2028 Pipeline Strengthening an Accelerating Growth Profile Rare, Specialty, and Compounded Products • 62% revenue growth Q4 • 57% revenue growth from • Largest quarterly revenue • High margin workhorse 2025 vs Q4 2024 Q4 2024 to Q4 2025 since
Slide 5: Financials & Outlook
Financials & Outlook 5 Corporate Presentation | March 2026
Slide 6: 2025 Key Financial Metrics (in thousands)
2025 Key Financial Metrics (in thousands) Consolidated Revenues Adjusted EBITDA $61,923 54% Growth $24.2 Adjusted ‘25 vs. ‘24 EBITDA in Q4 2025 36% Growth $272,303 ‘25 vs. ‘24 Q4 ‘25 $89.1 $199,614 $40,327 Operating expenses expected to remain stable Q3 ‘25 $28,119 $71.6 $130,193 $88,595 Q2 ‘25 $72,
Slide 7: Q4 & Full Year 2025 Key Growth Drivers Revenue
Q4 & Full Year 2025 Key Growth Drivers Revenue Rare, Specialty, and Compounded Q4 2025 Revenue $25.9M $35.9M $5.1M $22.2M Q4’25 vs Q3’25 Growth 14% 64% 36% -5% FY 2025 Revenue $88.7M $81.3M $9.9M $92.3M FY’25 vs FY’24 Growth 216% 65% 193% -22% 7 Corporate Presentation | March 2026
Slide 8: 2026 Financial Guidance
2026 Financial Guidance Full-Year 2026 Outlook H1 H2 Full-Year $133M-$153M $203M-$226M $350M-$365M Revenue (midpoint ~$214.5M) (midpoint ~$357.5M) (midpoint ~$143M) Full-Year Adjusted $80M-$100M EBITDA (midpoint ~$90M) 8 Corporate Presentation | March 2026
Slide 9: 2026 Financial Guidance Phasing
2026 Financial Guidance Phasing Q1 Q2 Q3 Q4 2024 Actual ~17% ~25% ~25% ~33% 2025 Actual ~18% ~23% ~26% ~33% 2026 Estimate 2026 quarterly revenue mix expected to be modestly more weighted toward H2 vs. 2024 and 2025 • Buy & Bill products working • IHEEZO loses pass-through • Q3 typically brings modes
Slide 10: Dry Eye Disease
Dry Eye Disease • VEVYE • FLAREX • FRESHKOTE 10 Corporate Presentation | March 2026
Slide 11: Addressing Dry Eye Disease
Addressing Dry Eye Disease FDA-approved to treat the signs FDA-approved for use in the Patented through 2039, & symptoms of Dry Eye Disease treatment of steroid- FRESHKOTE® Preservative Free (PF) responsive inflammatory is a lubricant eye drop that Intent to become the #1 conditions of the palpebral
Slide 12: VEVYE – A Best-in-Class Solution for Dry Eye Disease
VEVYE – A Best-in-Class Solution for Dry Eye Disease DED Patient Population The first and only water-free cyclosporine to treat Dry Eye prevalence is continuing to grow with aging the signs and symptoms of dry eye disease populations, increased screen time and poor diets • In a pre-clinical ex-vivo
Slide 13: VEVYE Q4 2025 Key Metrics
VEVYE Q4 2025 Key Metrics VEVYE Quarterly Revenue • Sustained Momentum: 14% increase in revenue in Q4 2025 vs Q3 2025 $25,900,000 • Robust Refill Rates Drive Durable Revenue: Average covered patient refilled ~9 times $22,600,000 in 20251 $21,500,000 • Rapid Provider Expansion: +115% $18,600,000 pres
Slide 14: Ocular Anesthesia
Ocular Anesthesia • IHEEZO 14 Corporate Presentation | March 2026
Slide 15: IHEEZO Overview
IHEEZO Overview • First approved use in the U.S. ophthalmic market of chloroprocaine hydrochloride • First branded ocular anesthetic approved for the U.S. market in nearly 14 years Sterile, single-patient-use, • IHEEZO Reimbursement: physician-administered, ophthalmic gel preparation o Permanent J-C
Slide 16: IHEEZO Q4 2025 Key Metrics
IHEEZO Q4 2025 Key Metrics IHEEZO Quarterly Customer Unit Demand(1) Year-over-Year Demand Improves (May 2023 Launch) Regardless of Q4 Stocking and Q1 Destocking Full Year 2025: Highlights: 201,215 • 56% year-over-year unit demand growth 56% Growth 2025 vs. 2024 • 49% year-over-year growth in the num
Slide 17: Expanding the IHEEZO TAM: In-Office Setting
Expanding the IHEEZO TAM: In-Office Setting In-Office Procedure Volume • Expanding IHEEZO into the office-based setting to materially increase the overall total addressable Anesthesia-relevant, reimbursed > 2.5M market (TAM) beyond retina procedures, such as: • Positioned to accelerate demand and dr
Slide 18: IHEEZO Retina Data Coming in 2026
IHEEZO Retina Data Coming in 2026 Intravitreal Injection Investigator-Initiated Trial (IIT) QUELL Intravitreal Injection Clinical Study • Prospective, Randomized clinical study • Phase 4, Multisite, Randomized, Double-Masked, Well-Controlled Study o Randomized 1:1 to receive either IHEEZO or propara
Slide 19: Ocular Steroids
Ocular Steroids • TRIESENCE (Injectable) • BYQLOVI (Topical) 19 Corporate Presentation | March 2026
Slide 20: TRIESENCE Overview
TRIESENCE Overview Expansion Into Ocular Inflammation Description:(1) • 7+ million annual potential U.S. use cases • The only FDA-approved preservative-free synthetic corticosteroid with separate reimbursement in all • Strong early clinical feedback: traditional settings of care o Clear market posit
Slide 21: TRIESENCE Q4 2025 Key Metrics
TRIESENCE Q4 2025 Key Metrics Q4 Highlights: TRIESENCE Quarterly Unit Demand1 • Largest quarterly revenue since Q4 2024 re-launch • Retina use continues to grow • Ocular inflammation is ramping and expected to drive majority 10,377 of new volume going forward 9,650 • ~5x growth in total unit volume
Slide 22: BYQLOVI – Best-in-Class Steroid
BYQLOVI – Best-in-Class Steroid First novel topical steroid marketed in over a decade Description: • BYQLOVI is an FDA-approved steroid to treat inflammation and pain after ocular surgery • Super potent and unique steroid: BYQLOVI is the only FDA-approved ocular steroid that utilizes clobetasol • Be
Slide 23: Anti-VEGFs
Anti-VEGFs • BYOOVIZ • OPUVIZ 23 Corporate Presentation | March 2026
Slide 24: Best-in-Class anti-VEGF Biosimilars
Best-in-Class anti-VEGF Biosimilars Recently entered into an agreement with Samsung Bioepis to acquire U.S. commercials rights to portfolio of ophthalmic biosimilars, including BYOOVIZ® (Lucentis Biosimilar) and OPUVIZ (Eylea Biosimilar) BYOOVIZ (ranibizumab-nuna) 0.05mL injection, the OPUVIZ (aflib
Slide 25: U.S. Ophthalmic Market Share-Anti-VEGFs
U.S. Ophthalmic Market Share-Anti-VEGFs ~8.5M Units Across All Products BYOOVIZ (Lucentis) & OPUVIZ (Eylea) offer a Unit Volume1 compelling value proposition and cost-effective alternative to current Anti-VEGF therapies & 2,550,000 2,550,000 compounded Avastin: • An FDA-approved, clinically-validate
Slide 26: Rare, Specialty, and Compounded Products
Rare, Specialty, and Compounded Products 26 Corporate Presentation | March 2026
Slide 27: Rare, Specialty, and Compounded
Rare, Specialty, and Compounded Specialty Steroids, NSAIDs, and Antihistamine, Antibiotics, and Recently Launched PharmaPack Program Anti-Inflammatories Antibiotic + Steroid Combination • Expands affordable access to FDA-approved products for millions of post-surgical patients • Decreases Harrow’s o
Slide 28: Pipeline
Pipeline 28 Corporate Presentation | March 2026
Slide 29: Harrow's Pipeline
Harrow’s Pipeline Product Indication Stage of Development Potential Launch Development G-MELT (MELT-300) Procedural (Ketamine + End of Phase 3 2028 Internal Sedation Midazolam ODT) YOCHIL (MELT-210) Sedation, Anxiolysis, and Phase 3 2028 Internal (Midazolam ODT) Amnesia H-N08 Uveitis, (Triamcinolone
Slide 30: G-MELT: IV- and Opioid-Free Procedural Sedation
G-MELT: IV- and Opioid-Free Procedural Sedation Fixed dose sublingual tablet combining 3 mg midazolam + 50 mg ketamine (non-opioid), two known and proven FDA-approved molecules in a novel form Technology Targets and Expansion Next Steps • Dissolves in seconds under the tongue, using • Initial target
Slide 31: Other Pipeline Programs
Other Pipeline Programs CR-01 YOCHIL (formerly, MELT-210) H-N08 (Triamcinolone Acetonide) (Conjunctival Delivery Device) Oral dissolving tablet: 3mg Midazolam New Presentation and formulation Drug delivery device for treatment of optimization of TRIESENCE in a rare disease oncology indication, a • M
Slide 32: Mike Biega
1A Burton Hills Blvd., Suite 200 Nashville, Tennessee 37215 Harrow.com Mike Biega Vice President of Investor Relations & Communications mbiega@harrowinc.com Direct: 617-913-8890 32 Corporate Presentation | March 2026